Kazuto Nishio|Kazuko Sakai|Yosuke Togashi - JoVE Visualize

Showing results (1-10 of 539) with videos related to

Pageof 54

Sort By:

Nihon Rinsho. Japanese Journal of Clinical Medicine|August 19, 2015

[PI3K and mTOR pathway and molecular targeted agents]Kazuto Nishio, Kazuko Sakai, Yosuke Togashi

Nihon Rinsho. Japanese Journal of Clinical Medicine|August 19, 2015

[Kinase inhibitors and their resistance]Yosuke Togashi, Kazuto Nishio

Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 26, 2017

[Clinical Application of NGS-Based Clinical Sequencing]Kazuto Nishio, Kazuko Sakai

Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2019

[Current Status and Future Direction of Cancer Genomic Medicine]Kazuto Nishio, Kazuko Sakai

Biochemical and Biophysical Research Communications|January 28, 2015

Inter- and intra-tumor profiling of multi-regional colon cancer and metastasisAkihiro Kogita, Yasumasa Yoshioka, Kazuko Sakai, et al.

Oncotarget|July 23, 2014

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survivalMasato Terashima, Yoshihiko Fujita, Yosuke Togashi, et al.

Springerplus|August 21, 2014

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell linesMasato Terashima, Kazuko Sakai, Yosuke Togashi, et al.

Lung Cancer (Amsterdam, Netherlands)|October 31, 2016

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutationJunko Tanizaki, Eri Banno, Yosuke Togashi, et al.

Drug Design, Development and Therapy|August 13, 2014

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceYosuke Togashi, Hidetoshi Hayashi, Kazuhiko Nakagawa, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutationYosuke Togashi, Hidetoshi Hayashi, Masato Terashima, et al.

Pageof 54

Showing results (1-10 of 539) with videos related to

Sort By:

Pageof 54

Nihon Rinsho. Japanese Journal of Clinical Medicine|August 19, 2015

[PI3K and mTOR pathway and molecular targeted agents]Kazuto Nishio, Kazuko Sakai, Yosuke Togashi

Nihon Rinsho. Japanese Journal of Clinical Medicine|August 19, 2015

[Kinase inhibitors and their resistance]Yosuke Togashi, Kazuto Nishio

Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 26, 2017

[Clinical Application of NGS-Based Clinical Sequencing]Kazuto Nishio, Kazuko Sakai

Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2019

[Current Status and Future Direction of Cancer Genomic Medicine]Kazuto Nishio, Kazuko Sakai

Biochemical and Biophysical Research Communications|January 28, 2015

Inter- and intra-tumor profiling of multi-regional colon cancer and metastasisAkihiro Kogita, Yasumasa Yoshioka, Kazuko Sakai, et al.

Oncotarget|July 23, 2014

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survivalMasato Terashima, Yoshihiko Fujita, Yosuke Togashi, et al.

Springerplus|August 21, 2014

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell linesMasato Terashima, Kazuko Sakai, Yosuke Togashi, et al.

Lung Cancer (Amsterdam, Netherlands)|October 31, 2016

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutationJunko Tanizaki, Eri Banno, Yosuke Togashi, et al.

Drug Design, Development and Therapy|August 13, 2014

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceYosuke Togashi, Hidetoshi Hayashi, Kazuhiko Nakagawa, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutationYosuke Togashi, Hidetoshi Hayashi, Masato Terashima, et al.

Pageof 54